Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
by Zacks Equity Research
Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.
Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies
by Zacks Equity Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.
SNY vs. PFE: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. PFE: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Caterpillar, Walmart, McDonald's, Pfizer and Marsh & McLennan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caterpillar, Walmart, McDonald's, Pfizer and Marsh & McLennan
BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss
by Zacks Equity Research
BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
Top Analyst Reports for Caterpillar, Walmart & McDonald's
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Caterpillar (CAT), Walmart (WMT) and McDonald's (MCD).
Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.
Is a Beat in Store for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress and launch plans for NKTR-181 when the company reports second-quarter results.
Economic and Earnings Date Deluge
by Zacks Equity Research
Economic and Earnings Date Deluge
Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More
by Mark Vickery
Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.
Stock Market News For Jul 30, 2019
by Zacks Equity Research
Ongoing U.S. and China trade negotiations and expectations around a Fed rate hike kept benchmarks on a tight leash on Monday.
Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer
by Zacks Equity Research
Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.
Pfizer (PFE) Beats on Q2 Earnings, to Merge Upjohn With Mylan
by Zacks Equity Research
Pfizer (PFE) beats estimates for second-quarter earnings but misses on sales. The company also lowers 2019 earnings and sales guidance.
What's in Store for Array BioPharma (ARRY) in Q4 Earnings?
by Zacks Equity Research
Array BioPharma's (ARRY) Braftovi-Mektovi combination therapy is likely to drive fourth-quarter sales.
Pfizer (PFE) Q2 Earnings Top Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 3.90% and -0.44%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of some older drugs will hurt the same.
Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.
Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment
by Kinjel Shah
AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.
Bristol-Myers (BMY) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the second quarter, primarily on robust sales of Opdivo and Eliquis. However, pipeline setbacks are a concern.
Glaxo (GSK) Beats on Q2 Earnings, Shingrix Sales Strong
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the second quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Can Pfizer's Q2 Earnings Help Boost PFE Stock in a Struggling Pharma Market?
by Zachary Stutler
Pfizer Inc. (PFE) is set to report its Q2 earnings results on Tuesday, July 30. Investors are hoping the report can boost PFE stock since it is down over 2% YTD.
What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
What to Expect from Sanofi's (SNY) Q2 Earnings
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.